查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947909

病毒學市場分析及預測（至2035年）：按類型、產品、服務、技術、應用、最終用戶、設備、流程和解決方案分類

Virology Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 354 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

病毒學市場預計將從2024年的32億美元成長到2034年的51億美元，複合年成長率約為4.2%。病毒學市場涵蓋病毒感染疾病的研究、診斷和治療，整合了基因測序、分子診斷和抗病毒療法等先進技術。病毒性疾病的日益普及以及對快速診斷解決方案的需求是推動該行業成長的主要因素。疫苗研發、抗病毒藥物創新和公共衛生舉措對於塑造市場動態和應對全球健康挑戰至關重要。

在對先進診斷解決方案和創新治療方法日益成長的需求推動下，病毒學市場持續穩定擴張。在這一市場格局中，診斷領域呈現最高成長率，其中分子診斷憑藉其準確性和快速出結果的優勢佔據主導。免疫檢測和血清學檢測也呈現類似的成長，這得益於它們在臨床環境中的廣泛應用。在治療領域，抗病毒藥物佔據主導地位，這反映了它們在病毒感染疾病管理中的關鍵作用。疫苗，尤其是針對新發和再發病毒的疫苗，是成長速度第二快的細分市場，這進一步印證了它們在醫療保健領域的重要性。包括mRNA平台在內的新型疫苗技術的出現，正進一步加速這一成長軌跡。此外，包括病毒學研究服務和工具在內的研究領域也正在蓬勃發展。這一成長得益於對病毒學研發投入的增加以及對新型抗病毒藥物的探索。基因組學和病毒學的融合正在推動創新突破，並為相關人員提供盈利的機會。

市場區隔
類型 診斷檢測、治療藥物研發、疫苗研究、抗病毒藥物研發
產品 設備、試劑、試劑盒、軟體及耗材
服務 合約研究、契約製造、諮詢、資料管理
科技 聚合酵素鏈鎖反應（PCR）、次世代定序（NGS）、細胞培養、酵素連結免疫吸附試驗（ELISA）、流式細胞技術
目的 人類健康、動物健康、植物病毒學、環境病毒學
最終用戶 醫院、診斷檢查室、研究機構、製藥和生物技術公司
裝置 PCR設備、定序儀、流式細胞儀、顯微鏡
過程 病毒分離、病毒純化、病毒擴增、病毒檢測
解決方案 感染疾病管理、疫情監測、疫苗研發平台、抗病毒藥物發現工具

病毒學市場正經歷由競爭性定價策略和創新產品推出驅動的動態變化。各公司正致力於拓展產品線，推出先進的診斷工具和抗病毒療法。這種策略擴張是為了因應日益成長的對有效病毒感染控制的需求。科技進步提高了產品療效和消費者信任度，進一步豐富了競爭格局。因此，醫療基礎設施發達的地區市場佔有率成長迅速。病毒學市場的競爭異常激烈，主要企業透過策略聯盟和研發爭奪主導。監管的影響，尤其是在北美和歐洲，對塑造市場動態至關重要。這些法規確保產品的安全性和有效性，並影響市場准入和競爭格局。與行業領導者的對標表明，各公司高度重視創新和合規性。研發投入的增加和新型治療方案的湧現正在推動市場成長。這一市場格局的特點是技術快速整合和法規結構不斷演變。

主要趨勢和促進因素：

由於病毒感染疾病的增加以及對有效診斷和治療方法的迫切需求，病毒學市場正經歷強勁成長。主要趨勢包括分子診斷技術的進步和快速就地檢驗的開發，這些技術有助於提高病毒性疾病的早期發現和管理。人工智慧 (AI) 和機器學習在病毒學研究中的應用，能夠建立更精準的預測模型並實現個人化治療方案。推動該市場成長的因素包括慢性病毒感染疾病（如愛滋病和肝炎）的日益流行，以及新發病毒大流行的威脅不斷加劇。病毒學研發投入的增加和發展中地區醫療基礎設施的擴張進一步促進了市場成長。此外，疫苗研發的重點和創新抗病毒療法的引入也為市場相關人員創造了盈利的機會。對次世代定序技術的需求也在激增，因為這些技術能夠提供全面的病毒基因組分析資訊，並有助於開發標靶治療。遠端醫療和數位平台的擴展也帶來了大量機遇，這些平台有助於改善患者獲得病毒學服務和遠端監測的途徑。隨著全球對疫情防範和應對的重視，病毒學市場預計將在持續的技術進步和策略合作的支持下實現持續擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 診斷測試
    • 治療藥物研發
    • 疫苗研究
    • 抗病毒藥物研發
  • 市場規模及預測：依產品分類
    • 裝置
    • 試劑
    • 成套工具
    • 軟體
    • 消耗品
  • 市場規模及預測：依服務分類
    • 合約研究
    • 契約製造
    • 諮詢
    • 資料管理
  • 市場規模及預測：依技術分類
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 細胞培養
    • ELISA
    • 流式細胞技術
  • 市場規模及預測：依應用領域分類
    • 人類健康
    • 動物健康
    • 植物病毒學
    • 環境病毒學
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 研究所
    • 製藥公司
    • 生技公司
  • 市場規模及預測：依設備分類
    • PCR裝置
    • 序列器
    • 流式細胞儀
    • 顯微鏡
  • 市場規模及預測：依製程分類
    • 病毒分離
    • 病毒純化
    • 病毒擴增
    • 病毒檢測
  • 市場規模及預測：按解決方案分類
    • 感染疾病控制
    • 疫情監測
    • 疫苗研發平台
    • 抗病毒藥物發現工具

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Bio NTech
  • Moderna
  • Novavax
  • Cure Vac
  • Inovio Pharmaceuticals
  • Vaxart
  • Vir Biotechnology
  • Valneva
  • Dynavax Technologies
  • Sorrento Therapeutics
  • Bavarian Nordic
  • Geo Vax Labs
  • Emergent Bio Solutions
  • Arcturus Therapeutics
  • Immunity Bio
  • Altimmune
  • VBI Vaccines
  • Tonix Pharmaceuticals
  • Icosavax
  • Atea Pharmaceuticals

第9章：關於我們

簡介目錄
Product Code: GIS32552

Virology Market is anticipated to expand from $3.2 billion in 2024 to $5.1 billion by 2034, growing at a CAGR of approximately 4.2%. The Virology Market encompasses the study, diagnosis, and treatment of viral infections, integrating advanced technologies like genomic sequencing, molecular diagnostics, and antiviral therapeutics. This sector is driven by the increasing prevalence of viral diseases and the need for rapid diagnostic solutions. Innovations in vaccine development and antiviral drugs, alongside public health initiatives, are pivotal in shaping market dynamics and addressing global health challenges.

The Virology Market is experiencing robust expansion, propelled by heightened demand for advanced diagnostic solutions and innovative treatment approaches. Within this landscape, the diagnostics segment is the top performer, with molecular diagnostics leading due to their precision and rapid results. Immunoassays and serological tests follow closely, driven by their widespread application in clinical settings. In the therapeutics segment, antiviral drugs dominate, reflecting their critical role in managing viral infections. Vaccines, particularly for emerging and re-emerging viruses, represent the second highest performing sub-segment, underscoring their importance in preventive healthcare. The advent of novel vaccine technologies, including mRNA platforms, further accelerates this growth trajectory. Additionally, the research segment, encompassing virology research services and tools, is gaining momentum. This growth is fueled by increased investment in virology R&D and the pursuit of new antiviral agents. The convergence of genomics and virology is fostering innovative breakthroughs, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeDiagnostic Testing, Therapeutic Development, Vaccine Research, Antiviral Drug Development
ProductInstruments, Reagents, Kits, Software, Consumables
ServicesContract Research, Contract Manufacturing, Consulting, Data Management
TechnologyPolymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cell Culture, ELISA, Flow Cytometry
ApplicationHuman Health, Animal Health, Plant Virology, Environmental Virology
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biotechnology Companies
DevicePCR Machines, Sequencers, Flow Cytometers, Microscopes
ProcessVirus Isolation, Virus Purification, Virus Amplification, Virus Detection
SolutionsInfectious Disease Management, Outbreak Surveillance, Vaccine Development Platforms, Antiviral Drug Discovery Tools

The virology market is witnessing a dynamic shift, driven by competitive pricing strategies and innovative product launches. Companies are focusing on broadening their portfolios with advanced diagnostic tools and antiviral treatments. This strategic expansion is catering to the rising demand for effective viral infection management. The market's competitive landscape is further enriched by technological advancements, which are enhancing product efficacy and consumer trust. As a result, regions with robust healthcare infrastructures are experiencing a surge in market share. Competition in the virology market is intense, with leading firms vying for dominance through strategic alliances and research collaborations. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure product safety and efficacy, thus impacting market entry and competition. Benchmarking against industry leaders reveals a focus on innovation and compliance. The market is poised for growth, driven by increased R&D investments and the emergence of novel therapeutic solutions. The landscape is characterized by rapid technological integration and evolving regulatory frameworks.

Geographical Overview:

The virology market is witnessing substantial growth across various regions, each with unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and significant investments in virology research. The presence of major pharmaceutical companies further accelerates market expansion. Europe follows closely, with strong governmental support for research and development in virology, fostering a robust ecosystem. The region's focus on public health and pandemic preparedness enhances its market appeal. In the Asia Pacific, the market is expanding rapidly, fueled by increasing healthcare expenditure and a growing focus on infectious disease control. Emerging economies like China and India are investing heavily in virology research and infrastructure. Latin America and the Middle East & Africa are emerging markets with increasing potential. In Latin America, the rise in public health initiatives is driving virology market growth, while the Middle East & Africa are recognizing the importance of virology in addressing regional health challenges.

Global tariffs and geopolitical tensions are intricately influencing the virology market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing their virology research capabilities to mitigate reliance on foreign technologies, driven by trade barriers and a focus on self-reliance. China is investing heavily in domestic biotechnology innovations, accelerating its virology advancements amid export restrictions. Taiwan, while a crucial player in biotech components, remains vulnerable to regional geopolitical risks. The global virology market is experiencing robust growth due to heightened health awareness and pandemic preparedness. By 2035, the market is expected to be characterized by increased regional collaboration and technological advancements. Middle East conflicts pose potential risks to global supply chains, particularly affecting energy prices, which could impact manufacturing costs and logistics.

Key Trends and Drivers:

The virology market is experiencing robust growth, driven by increasing incidences of viral infections and the urgent need for effective diagnostics and therapeutics. Key trends include advancements in molecular diagnostics and the development of rapid point-of-care testing, which are enhancing early detection and management of viral diseases. The integration of artificial intelligence and machine learning in virology research is enabling more accurate predictive models and personalized treatment approaches. Drivers of this market include the rising prevalence of chronic viral infections, such as HIV and hepatitis, and the growing threat of emerging viral pandemics. Increased funding for virology research and the expansion of healthcare infrastructure in developing regions are further propelling market growth. Additionally, the focus on vaccine development and the adoption of innovative antiviral therapies are creating lucrative opportunities for market players. The demand for next-generation sequencing technologies is also surging, as they provide comprehensive insights into viral genomics and facilitate the development of targeted therapies. Opportunities are abundant in expanding telehealth and digital platforms, which enhance patient access to virology services and support remote monitoring. With the global emphasis on pandemic preparedness and response, the virology market is poised for sustained expansion, underpinned by continuous technological advancements and strategic collaborations.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic Testing
    • 4.1.2 Therapeutic Development
    • 4.1.3 Vaccine Research
    • 4.1.4 Antiviral Drug Development
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Reagents
    • 4.2.3 Kits
    • 4.2.4 Software
    • 4.2.5 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Research
    • 4.3.2 Contract Manufacturing
    • 4.3.3 Consulting
    • 4.3.4 Data Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Polymerase Chain Reaction (PCR)
    • 4.4.2 Next-Generation Sequencing (NGS)
    • 4.4.3 Cell Culture
    • 4.4.4 ELISA
    • 4.4.5 Flow Cytometry
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Human Health
    • 4.5.2 Animal Health
    • 4.5.3 Plant Virology
    • 4.5.4 Environmental Virology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Companies
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 PCR Machines
    • 4.7.2 Sequencers
    • 4.7.3 Flow Cytometers
    • 4.7.4 Microscopes
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Virus Isolation
    • 4.8.2 Virus Purification
    • 4.8.3 Virus Amplification
    • 4.8.4 Virus Detection
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Infectious Disease Management
    • 4.9.2 Outbreak Surveillance
    • 4.9.3 Vaccine Development Platforms
    • 4.9.4 Antiviral Drug Discovery Tools

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Bio NTech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Moderna
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Novavax
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cure Vac
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Inovio Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vaxart
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Vir Biotechnology
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Valneva
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dynavax Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sorrento Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bavarian Nordic
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Geo Vax Labs
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Emergent Bio Solutions
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Arcturus Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Immunity Bio
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Altimmune
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 VBI Vaccines
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tonix Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Icosavax
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Atea Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us